Zoetis’s Clocks Mixed Q2 Earnings, Lowers FY22 Profit Outlook
Zoetis Inc (NYSE: ZTS) has reported Q2 FY22 revenue of $2.05 billion, an increase of 5% Y/Y, almost in line with…
Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings
Organon & Co’s (NYSE:OGN) Q2 sales decreased 1% Y/Y to $1.59 billion, beating the consensus of $1.54 billion. The sales…
Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm
Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists…
FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder
The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…
Several S&P 500 Companies Step Up Capital Spending Faster Than Share Buybacks
Big U.S. companies, including Alphabet Inc (NASDAQ:GOOG), General Motors Company (NYSE:GM), and PepsiCo Inc (NASDAQ:PEP), have increased spending on real estate, equipment, and technology.…
FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.
Sarepta’s Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward…
Novo Nordisk Shares Fall After Q2 Earnings Despite Raised Annual Outlook
Novo Nordisk A/S (NYSE:NVO) reported Q2 sales of DKK41.27 billion, +25% Y/Y (+15% on a constant currency basis). Operating profit…
This Stock Offers ‘Attractive Opportunity For Small Cap Growth Exposure’ In Healthcare Services
Stephens initiated coverage on ModivCare Inc (NASDAQ:MODV) with an Overweight rating and a $145 price target. ModivCare represents an attractive opportunity for…
Intercept Shares Jump After Reissuing Annual Guidance
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) completed the sale of its international business for $405 million in upfront consideration.